The companies entered into a mutually executed memorandum of understanding. This agreement transitions all commercialization and distribution of the Eversense 365 long-term implantable continuous glucose monitor (CGM) and future products from Ascensia to Senseonics.
Ascensia became the exclusive global distributor for Eversense products, including the year-long Eversense 365 implant, in 2020. After five years, though, and with new products (Gemini and Freedom) on the horizon, Senseonics — one of the largest diabetes tech companies in the world — is now taking commercial efforts into its own hands.
Under the agreement, Senseonics assumes responsibility for all global sales, marketing and commercialization in the U.S. on Jan. 1, 2026. It plans to use transition service agreements through Ascensia until fully established in markets outside the U.S.
Brian Hansen, presdient of CGM at Ascensia, would join Senseonics as chief commercial officer (CCO) on Jan. 1, 2026. The companies expect to work together to develop definitive documentation for the planned transaction.
Read more about Senseonics and the rest of the diabetes tech industry in our free Diabetes Technology Special Report.
Senseonics said that, as awareness and momentum builds with Eversense 365, its go-to-market approach is diverging from Ascensia’s core blood glucose monitoring business. The company believes that it requires strategic investment and fully dedicated commercial efforts, plus tight vertical integration.
By unifying the Eversense business and incorporating commercial activities directly within Senseonics, the companies believe Eversense would achieve more growth and realize its full potential faster than under the current structure. Senseonics expects to better position itself to meet payer, provider and patient needs. Owning the commercial channel could also increase topline revenue and expand margins by eliminating revenue sharing.
The company expects immediate revenue improvement and gross margin expansion to 50% in 2026. It reaffirmed its 2025 guidance for revenues between $34 million and $38 million.
Commentary from Senseonics and Ascensia officials
Tim Goodnow, president and CEO of Senseonics said:
“I’m thrilled to bring Eversense 365 commercialization back in-house and directly control investment in growing the brand to better serve the needs of patients and providers. With Brian to remain at the helm of Senseonics’ commercialization efforts, we are confident that this move will yield benefits for our customers and our shareholders. Eversense 365 is the world’s first and only year-long continuous glucose monitor, deserving a dedicated sales force and commercial infrastructure. We truly appreciate the partnership and investment that PHC Group and Ascensia has made in Senseonics. We look forward to welcoming the talented commercial team to Senseonics to help ensure a positive experience for our customers, while working to accelerate growth of Eversense 365.”
Koichiro Sato, COO and chief strategy officer of PHC Group and CEO of Ascensia Diabetes Care, said:
“We are very proud to have worked with Senseonics on commercializing Eversense and are committed to supporting Senseonics in establishing their own commercial operations and smoothly transitioning to them under the planned agreements. The Eversense long-term CGM system can help overcome many frustrations in diabetes management and we believe in the growth potential of Eversense and remain invested in Senseonics.”
The analysts’ take
BTIG analysts Marie Thibault, Sam Eiber and Alexandra Pang maintain a “Neutral” rating for Senseonics.
The analysts expect more information on a conference call hosted by the companies, including details on termination fees, TSA costs or similar. They expect in-house commercial infrastructure to allow for higher revenue recognition, as the companies said. However, they do question how much savings will be offset by operating expenses required to support the sales organization and commercial efforts.
“In our view, Senseonics will need a large, high-touch salesforce and marketing teams to be successful in taking meaningful share from legacy systems or to expand the CGM-using population,” the analysts wrote. “With this move, Senseonics is doubling down on its view that the one-year sensor will finally enable an inflection in patient demand for the implantable glucose monitor, and with the recent $78M financing and expanded $100M debt facility (prior $50M term loan facility, of which $35M has been drawn), the company has the capital to bet big.
The analysts also note that management expects the majority of Ascensia’s sales and marketing teams, which cover 45 territories within the U.S., to join the organization and ensure a relatively smooth transition.
“We understand this strategic shift and think it allows for greater focus and increased patient/prescriber awareness,” the analysts said. “[Senseonics] is also taking on more costs with this transaction, so we hope this approach will produce an inflection in patient demand. We continue to remain on the sidelines until the commercial strategy shows a consistent inflection.”
